X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-07-11 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $3.14 | +10,000 | 943,334 | +1% | +$31,400 | ||||||
2025-07-10 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $57.50 | -2,000 | 65,530 | -3% | -$115,000 | ||||||
| D | 2025-07-10 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $22.66 | -1,000 | 23,000 | -4% | -$22,655 | |||||
| D | 2025-07-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $71.08 | -2,200 | 0 | -100% | -$156,376 | |||||
| D | 2025-07-10 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $300.31 | -11,000 | 36,781 | -23% | -$3,303,394 | |||||
2025-07-10 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Dir | P - Purchase | $9.00 | +2,777,777 | 9,003,418 | +45% | +$24,999,993 | ||||||
2025-07-14 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $64.88 | -400 | 78,945 | -1% | -$25,952 | ||||||
| DM | 2025-07-10 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $15.05 | -28,750 | 115,468 | -20% | -$432,700 | |||||
2025-07-11 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.15 | +5,000 | 574,925 | +1% | +$15,750 | ||||||
2025-07-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $51.16 | -30,000 | 520,757 | -5% | -$1,534,895 | ||||||
2025-07-10 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $125.00 | -934 | 46,456 | -2% | -$116,750 | ||||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $4.80 | +84 | 32,653 | 0% | +$404 | |||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $4.80 | +168 | 5,699,428 | 0% | +$807 | |||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $4.80 | +168 | 43,336 | 0% | +$807 | |||||
| M | 2025-06-02 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $4.83 | +935 | 286,633 | 0% | +$4,513 | |||||
2025-07-09 | TRDA | Entrada Therapeutics, Inc. | Parmar Kush | Dir, 10% | S - Sale | $7.50 | -27,000 | 4,256,379 | -1% | -$202,554 | ||||||
2025-07-09 | TRDA | Entrada Therapeutics, Inc. | 5Am Ventures V, L.P. | 10% | S - Sale | $7.50 | -27,000 | 4,256,379 | -1% | -$202,554 | ||||||
2025-07-09 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $253.38 | -27,802 | 53,867,649 | 0% | -$7,044,591 | ||||||
| D | 2025-07-09 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $37.99 | -11,914 | 61,271 | -16% | -$452,601 | |||||
| D | 2025-07-09 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $55.33 | -34,800 | 161,828 | -18% | -$1,925,525 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale+OE | $80.48 | -42,120 | 116,915 | -26% | -$3,389,756 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $77.78 | -7,969 | 8,509 | -48% | -$619,851 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | German Christopher Paul | Corporate Controller, CAO | S - Sale+OE | $80.75 | -3,817 | 922 | -81% | -$308,217 | |||||
| DM | 2025-07-09 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $80.31 | -7,645 | 60,956 | -11% | -$613,986 | |||||
| D | 2025-07-09 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $77.13 | -15,572 | 19,209 | -45% | -$1,201,062 | |||||
| DM | 2025-07-09 | MRUS | Merus N.V. | Silverman Peter B. | COO, GC | S - Sale+OE | $55.00 | -23,500 | 0 | -100% | -$1,292,500 | |||||
2025-07-09 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale | $15.69 | -32,979 | 369,595 | -8% | -$517,523 | ||||||
| M | 2025-07-08 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $3.53 | -9,522 | 204,229 | -4% | -$33,649 | |||||
| M | 2025-07-08 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $3.53 | -7,817 | 164,894 | -5% | -$27,624 | |||||
2025-07-09 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale | $15.69 | -30,250 | 127,939 | -19% | -$474,698 | ||||||
| M | 2025-07-08 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $3.53 | -47,172 | 7,180,901 | -1% | -$166,702 | |||||
2025-07-09 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $1.60 | +5,000 | 1,002,410 | +1% | +$8,024 | ||||||
| M | 2025-07-10 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.01 | +198,737 | 117,041,210 | 0% | +$994 | |||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Silverstein Christine Berni | Dir | S - Sale | $5.86 | -13,093 | 120,479 | -10% | -$76,669 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.86 | -69,420 | 1,234,341 | -5% | -$406,503 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.86 | -25,411 | 479,168 | -5% | -$148,799 | ||||||
2025-07-08 | ABEO | Abeona Therapeutics Inc. | Wuchterl Donald A. | Dir | S - Sale | $5.82 | -5,176 | 145,436 | -3% | -$30,147 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Charles Faith L. | Dir | S - Sale | $5.86 | -10,738 | 139,094 | -7% | -$62,879 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.86 | -17,428 | 360,817 | -5% | -$102,053 | ||||||
2025-07-09 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.86 | -13,093 | 77,252 | -14% | -$76,669 | ||||||
2025-07-08 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Plassche Douglas | EVP Operations | S - Sale | $0.58 | -200,000 | 2,300,000 | -8% | -$115,800 | ||||||
2025-07-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $19.79 | -6,667 | 296,642 | -2% | -$131,951 | ||||||
| D | 2025-07-07 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $51.09 | -12,500 | 167,124 | -7% | -$638,661 | |||||
2025-07-07 | MURA | Mural Oncology Plc | Loew Caroline | CEO | S - Sale | $2.43 | -12,531 | 293,059 | -4% | -$30,475 | ||||||
| M | 2025-07-08 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.18 | +33,044 | 1,700,000 | +2% | +$5,938 | |||||
| D | 2025-07-07 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $95.86 | -57,764 | 84,017 | -41% | -$5,537,460 | |||||
| D | 2025-07-07 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $5.67 | -6,500 | 0 | -100% | -$36,855 | |||||
| D | 2025-07-03 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $55.09 | -5,200 | 161,828 | -3% | -$286,454 | |||||
2025-07-07 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | S - Sale | $1.50 | -29,002 | 2,292,446 | -1% | -$43,625 | ||||||
2025-07-07 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $0.45 | -2,011 | 86,809 | -2% | -$905 | ||||||
| D | 2025-07-08 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $33.76 | -2,000 | 140,610 | -1% | -$67,520 | |||||
2025-07-03 | BPMC | Blueprint Medicines Corp | Rossi Christina | COO | S - Sale | $128.25 | -1,172 | 63,546 | -2% | -$150,309 | ||||||
2025-07-03 | BPMC | Blueprint Medicines Corp | Carter Percy H. | Chief Scientific Officer | S - Sale | $128.25 | -1,051 | 53,155 | -2% | -$134,791 | ||||||
2025-07-03 | RCKT | Rocket Pharmaceuticals, Inc. | Ondrey Aaron | CFO | S - Sale | $2.88 | -1,477 | 128,173 | -1% | -$4,257 | ||||||
| D | 2025-07-03 | GLTO | Galecto, Inc. | Schambye Hans T. | CEO | S - Sale+OE | $3.38 | -735 | 4,022 | -15% | -$2,484 | |||||
| D | 2025-07-03 | GLTO | Galecto, Inc. | Winslow Garrett | GC | S - Sale+OE | $3.39 | -260 | 1,429 | -15% | -$881 | |||||
| D | 2025-07-03 | GLTO | Galecto, Inc. | Firmani Lori | Interim CFO | S - Sale+OE | $3.39 | -147 | 692 | -18% | -$498 | |||||
| M | 2025-07-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $7.29 | -5,461 | 480,804 | -1% | -$39,836 | |||||
| M | 2025-07-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CTO | S - Sale | $7.28 | -1,791 | 120,079 | -1% | -$13,036 | |||||
| M | 2025-07-02 | BCYC | Bicycle Therapeutics Plc | Milnes Alistair | COO | S - Sale | $7.25 | -2,115 | 95,502 | -2% | -$15,333 | |||||
| M | 2025-07-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $7.21 | -722 | 53,825 | -1% | -$5,206 | |||||
| M | 2025-07-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | Chief Accounting Officer | S - Sale | $7.20 | -306 | 31,521 | -1% | -$2,205 | |||||
2025-07-02 | BCYC | Bicycle Therapeutics Plc | Young Alethia | CFO | S - Sale | $7.09 | -204 | 45,186 | 0% | -$1,446 | ||||||
| D | 2025-07-03 | MLTX | Moonlake Immunotherapeutics | Moukheibir Catherine | Dir | S - Sale+OE | $48.79 | -23,500 | 0 | -100% | -$1,146,565 | |||||
2025-07-02 | IMRX | Immuneering Corp | Hausman Diana | Dir | P - Purchase | $3.61 | +5,500 | 5,500 | New | +$19,863 | ||||||
2025-07-02 | IMRX | Immuneering Corp | Neufeld Leah R | CHIEF PEOPLE OFFICER | P - Purchase | $3.57 | +700 | 10,729 | +7% | +$2,499 | ||||||
2025-07-01 | JUNS | Jupiter Neurosciences, Inc. | Silva Alison D. | Pres + Chief Business Officer | P - Purchase | $1.03 | +750 | 112,777 | +1% | +$772 | ||||||
| D | 2025-07-01 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $73.51 | -100 | 5,487 | -2% | -$7,351 | |||||
| D | 2025-07-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $73.51 | -100 | 10,066 | -1% | -$7,351 | |||||
| D | 2025-07-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $73.45 | -205 | 117,398 | 0% | -$15,058 | |||||
2025-07-01 | PMVP | Pmv Pharmaceuticals, Inc. | Ticktin Robert | GC, COO | S - Sale | $1.06 | -23,151 | 98,695 | -19% | -$24,651 | ||||||
2025-07-01 | PMVP | Pmv Pharmaceuticals, Inc. | Jalota Deepika | Chief Development Officer | S - Sale | $1.06 | -33,065 | 89,959 | -27% | -$35,198 | ||||||
2025-07-01 | PMVP | Pmv Pharmaceuticals, Inc. | Carulli Michael | CFO | S - Sale | $1.06 | -28,249 | 60,146 | -32% | -$30,077 | ||||||
2025-07-01 | PMVP | Pmv Pharmaceuticals, Inc. | Mack David Henry | Pres, CEO | S - Sale | $1.06 | -58,411 | 906,333 | -6% | -$62,179 | ||||||
| D | 2025-07-01 | LFVN | Lifevantage Corp | Aure Carl | CFO | S - Sale+OE | $13.39 | -2,746 | 133,303 | -2% | -$36,769 | |||||
| DM | 2025-07-02 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $48.63 | -1,041 | 2,426 | -30% | -$50,624 | |||||
2025-07-01 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | SVP, Commercial Strategy | S - Sale | $52.88 | -2,000 | 29,891 | -6% | -$105,760 | ||||||
2025-07-02 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $23.47 | -500 | 77,531 | -1% | -$11,734 | ||||||
| D | 2025-07-02 | RYTM | Rhythm Pharmaceuticals, Inc. | Garfield Alastair | Chief Scientific Officer | S - Sale+OE | $64.81 | -1,319 | 3,126 | -30% | -$85,483 | |||||
| M | 2025-07-01 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $42.63 | -80,000 | 5,931,537 | -1% | -$3,410,450 | |||||
| D | 2025-07-01 | SPRY | Ars Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Officer | S - Sale+OE | $16.99 | -15,000 | 10,315 | -59% | -$254,861 | |||||
2025-07-02 | KZR | Kezar Life Sciences, Inc. | Chiang Pichi Luo | SVP, Corporate Controller | S - Sale | $4.28 | -264 | 2,711 | -9% | -$1,130 | ||||||
2025-07-02 | KZR | Kezar Life Sciences, Inc. | Schiller Mark C. | COO | S - Sale | $4.28 | -561 | 2,739 | -17% | -$2,401 | ||||||
| M | 2025-07-01 | BRFG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | S - Sale | $1.57 | -20,998 | 2,321,448 | -1% | -$32,911 | |||||
| D | 2025-07-02 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $35.23 | -7,072 | 536,962 | -1% | -$249,147 | |||||
| D | 2025-07-01 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $34.17 | -4,091 | 61,271 | -6% | -$139,789 | |||||
2025-07-03 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Pres, CEO | S - Sale | $27.80 | -26,889 | 2,388,014 | -1% | -$747,633 | ||||||
2025-07-03 | VKTX | Viking Therapeutics, Inc. | Zante Greg | CFO | S - Sale | $27.76 | -4,266 | 168,660 | -2% | -$118,428 | ||||||
2025-07-03 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | COO | S - Sale | $27.77 | -4,266 | 377,535 | -1% | -$118,473 | ||||||
2025-07-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $107.63 | -1,000 | 436,973 | 0% | -$107,630 | ||||||
2025-07-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Chief Medical Officer | S - Sale | $4.27 | -853 | 52,464 | -2% | -$3,640 | ||||||
2025-07-01 | JUNS | Jupiter Neurosciences, Inc. | Rosen Christer | CEO, COB, 10% | P - Purchase | $1.02 | +3,600 | 11,078,892 | 0% | +$3,667 | ||||||
| D | 2025-07-02 | ANAB | Anaptysbio, Inc | Renton Hollings | Dir | S - Sale+OE | $23.57 | -20,925 | 4,965 | -81% | -$493,191 | |||||
| A | 2025-07-01 | RMTI | Rockwell Medical, Inc. | Chole Timothy | SVP, CCO | S - Sale | $0.82 | -2,868 | 128,167 | -2% | -$2,352 | |||||
| A | 2025-07-01 | RMTI | Rockwell Medical, Inc. | Strobeck Mark | Pres, CEO | S - Sale | $0.82 | -6,926 | 337,752 | -2% | -$5,679 | |||||
| A | 2025-07-01 | RMTI | Rockwell Medical, Inc. | Neri Jesse | SVP, CFO | S - Sale | $0.82 | -886 | 126,614 | -1% | -$727 | |||||
2025-07-02 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.11 | +8,000 | 2,503,412 | 0% | +$880 | ||||||
| M | 2025-07-01 | IMRX | Immuneering Corp | Zeskind Benjamin J. | Pres, CEO, 10% | P - Purchase | $3.49 | +10,000 | 3,207,779 | 0% | +$34,879 | |||||
| D | 2025-07-02 | CLRB | Cellectar Biosciences, Inc. | Caruso James V | CEO | P - Purchase | $4.99 | +10,000 | 11,638 | +611% | +$49,900 | |||||
| D | 2025-07-02 | CLRB | Cellectar Biosciences, Inc. | Longcor Jarrod | COO | P - Purchase | $4.99 | +10,000 | 12,768 | +361% | +$49,900 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |